Prolactin

What Hyperprolactinemia Actually Feels Like

Nobody sets out to "experience" prolactin. You experience it when something goes wrong -- when a medication you need raises it above where it should be, when a small tumor on your pituitary starts overproducing it, or when the cocktail of substances you are using disrupts the dopamine system that normally keeps it in check. And the experience, as described by the thousands of people who have lived through it, is less a dramatic crisis than a slow, insidious erosion of the things that make you feel like yourself.

The first thing most people notice is the sexual dysfunction. It does not arrive suddenly. Libido fades gradually -- you stop thinking about sex, stop noticing attraction, stop initiating. In men, erections become unreliable and then scarce. Orgasms, when they happen at all, feel muted and mechanical. Women report vaginal dryness, loss of arousal, and the same flatline of desire. This is not a bad week or a stressful month. This is a pharmacological shutdown of the hypothalamic-pituitary-gonadal axis, and Reddit threads on r/Prolactinoma and r/antipsychiatry are filled with people who spent months or years attributing it to depression, relationship problems, or aging before a blood test revealed the real cause.

The fatigue is the second pillar. It is not sleepiness -- it is a bone-deep exhaustion that sleep does not fix. You wake up tired. Coffee provides a temporary and inadequate patch. By afternoon, the couch has gravitational pull. People describe it as "running on 60% battery," "like someone turned down my brightness setting," or simply "feeling biochemically wrong in a way I could not articulate." The fatigue compounds the sexual dysfunction: you do not have the energy for intimacy even if the desire were present.

Then there is the mood. Depression, anxiety, irritability -- sometimes all three cycling unpredictably. The depression of hyperprolactinemia has a particular quality that patients distinguish from primary depression: it feels more physical, more hormonal, more like your brain's chemistry is off rather than your life being wrong. Motivation drains away. Things that used to matter stop mattering. The inner monologue goes quiet, not in a meditative way but in a way that feels like absence.

The cognitive effects complete the picture. "Brain fog" is the universal descriptor -- difficulty concentrating, reduced working memory, the sense that your thoughts are moving through syrup. People describe losing words mid-sentence, reading the same paragraph three times, forgetting what they walked into a room to do. These are the same complaints that accompany hypothyroidism and chronic fatigue syndrome, and the overlap is not coincidental: all three involve disruption of hypothalamic-pituitary-target organ feedback loops.

For some, there are visible signs. Galactorrhea -- spontaneous breast milk production -- is deeply distressing, particularly for men who discover it unexpectedly. Gynecomastia develops slowly and carries enormous psychological weight in male patients. Weight gain accumulates without obvious dietary changes. Hair may thin. Skin may change texture.

The cruelest aspect of hyperprolactinemia is its invisibility. You look fine. Blood work looks normal if nobody thinks to check prolactin. And the symptoms -- fatigue, low libido, depression, brain fog -- overlap perfectly with a dozen more common diagnoses. The median time from symptom onset to prolactin-related diagnosis is measured in years, not months. One recurring theme across every support community: "I wish someone had checked my prolactin levels sooner."

Recovery, once prolactin is normalized, is typically dramatic. People describe feeling "like a light switch was flipped" within weeks of starting cabergoline. Libido returns. Energy returns. The fog lifts. It is one of the most satisfying treatment responses in all of endocrinology -- a measurable hormone, a targeted drug, and a patient who goes from barely functional to fully themselves. The relief, more than anything, is what fills the recovery threads.

The Dopamine-Prolactin Axis

Prolactin regulation is dominated by a single principle: tonic inhibition by dopamine. This distinguishes prolactin from every other anterior pituitary hormone, which require hypothalamic releasing factors to enter the circulation. Prolactin is the opposite -- lactotroph cells want to secrete it continuously, and only the constant delivery of dopamine from the tuberoinfundibular dopaminergic (TIDA) neurons in the arcuate nucleus of the hypothalamus prevents them from doing so.

Dopamine travels from the arcuate nucleus through the infundibulum to the anterior pituitary via the hypophyseal portal system, where it binds D2 receptors on lactotroph cell membranes. D2 receptor activation triggers a cascade of intracellular events: inhibition of adenylyl cyclase reduces cAMP, which suppresses prolactin gene transcription. Simultaneously, dopamine activates potassium channels and inhibits voltage-gated calcium channels, hyperpolarizing the cell and reducing calcium-dependent exocytosis of prolactin-containing vesicles. The net effect is a two-pronged suppression -- less prolactin is made and less of what exists is released .

Short-Loop Feedback

Prolactin itself completes the circuit through short-loop feedback. Circulating prolactin activates prolactin receptors on TIDA neurons, stimulating dopamine synthesis and release. When prolactin levels rise, more dopamine is produced to bring them back down. When prolactin falls, dopamine output decreases, allowing prolactin to recover. This autoregulatory loop is the reason that prolactin levels oscillate in a stable range under normal conditions .

Prolactin-Releasing Factors

While dopamine dominates, several factors stimulate prolactin release:

• Thyrotropin-releasing hormone (TRH) -- This is why hypothyroidism causes hyperprolactinemia. TRH stimulates both TSH and prolactin release. When thyroid hormone levels fall, TRH rises and drags prolactin up with it
• Vasoactive intestinal peptide (VIP) -- Acts as a prolactin-releasing factor, particularly during suckling
• Estrogen -- Directly stimulates lactotroph proliferation and prolactin gene transcription. This explains why hyperprolactinemia is more common in women and why pregnancy causes physiological prolactin elevation
• Serotonin -- 5-HT pathways stimulate prolactin release, which is why SSRIs can cause mild hyperprolactinemia
• Opioid peptides -- Endogenous and exogenous opioids stimulate prolactin by inhibiting TIDA dopamine neurons via mu receptors. This is the mechanism behind opioid-induced hyperprolactinemia

Prolactin Receptor Signaling

The prolactin receptor (PRLR) is a type I cytokine receptor that signals through the JAK2/STAT5 pathway. When prolactin binds, two receptor molecules dimerize, activating Janus kinase 2 (JAK2), which phosphorylates STAT5 (Signal Transducer and Activator of Transcription 5). Phosphorylated STAT5 dimerizes and translocates to the nucleus, where it drives transcription of prolactin-responsive genes including milk protein genes in mammary tissue, immune modulatory genes in lymphocytes, and metabolic genes in adipose tissue. This cytokine-like signaling is why prolactin has such wide-ranging effects beyond lactation .

Pharmacokinetics

Prolactin is secreted in a pulsatile fashion with a circadian rhythm: levels are lowest in the late morning, rise through the afternoon, and peak during sleep (particularly during REM sleep). The plasma half-life of monomeric prolactin is approximately 25-50 minutes. Clearance occurs primarily through the liver (approximately 75%) and kidneys (approximately 25%). The daily secretion rate in non-pregnant adults ranges from 200 to 536 micrograms per day .

Molecular Forms

Prolactin circulates in three major forms:

• Monomeric prolactin (little prolactin) -- 23 kDa, the bioactive form, accounts for 80-95% of circulating prolactin
• Big prolactin -- approximately 50 kDa, dimeric form with reduced bioactivity
• Big-big prolactin (macroprolactin) -- greater than 100 kDa, prolactin complexed with IgG antibodies. Macroprolactin has minimal biological activity but is detected by standard immunoassays, causing falsely elevated readings. This is the most common cause of asymptomatic "hyperprolactinemia" and should be ruled out before initiating treatment

References

1. Ben-Jonathan N, Hnasko R. "Dopamine as a prolactin (PRL) inhibitor." Endocrine Reviews. 2001;22(6):724-763.
2. Grattan DR. "60 Years of neuroendocrinology: the hypothalamo-prolactin axis." Journal of Endocrinology. 2015;226(2):T101-T122.
3. Molitch ME. "Drugs and prolactin." Pituitary. 2008;11(2):209-218.
4. Brooks CL. "Molecular mechanisms of prolactin and its receptor." Endocrine Reviews. 2012;33(4):504-525.
5. Freeman ME et al. "Prolactin: structure, function, and regulation of secretion." Physiological Reviews. 2000;80(4):1523-1631.
6. Karavitaki N et al. "Macroprolactin revisited." Clinical Endocrinology. 2006;65(4):524-529.

Discovery and Early Confusion (1928-1970)

The story of prolactin begins with pigeons. In 1928-1929, Oscar Riddle and colleagues at the Carnegie Institution identified a substance from pituitary extracts that stimulated the pigeon crop sac -- a glandular structure in birds that produces "crop milk" to feed chicks. By 1933, Riddle had isolated the factor, developed a bioassay based on crop sac weight, and named it prolactin. It was one of the earliest pituitary hormones to be identified.

But prolactin then fell into a four-decade limbo in human endocrinology. The problem was growth hormone (GH). Both are 199-amino-acid single-chain polypeptides with similar tertiary structures and overlapping biological activities. Throughout the 1940s-1960s, most endocrinologists believed that human prolactin did not exist as a separate hormone -- that growth hormone itself mediated lactogenic effects in humans. This was not unreasonable: early immunoassays could not distinguish between the two, and GH preparations did show lactogenic activity in bioassays.

Confirmation as a Distinct Human Hormone (1970-1972)

The turning point came in 1970-1972 when Henry Friesen and colleagues at McGill University developed a radioimmunoassay specific enough to distinguish human prolactin from human GH. They demonstrated that prolactin was indeed a separate circulating hormone with independent regulation, confirming what veterinary and basic science researchers had argued for decades. This discovery transformed clinical endocrinology: suddenly, previously unexplained cases of galactorrhea, amenorrhea, and infertility had a biochemical explanation.

The Dopamine Connection (1950s-1980s)

The second major chapter was understanding prolactin's regulation. In the 1950s and 1960s, researchers discovered that hypothalamic extracts inhibited rather than stimulated prolactin release -- the opposite of what was expected for a pituitary hormone. By the 1970s, dopamine was identified as the prolactin-inhibiting factor (PIF), and the tuberoinfundibular dopaminergic pathway was mapped. This discovery had immediate clinical implications: if dopamine suppressed prolactin, then dopamine agonists could treat hyperprolactinemia.

The Therapeutic Revolution (1970s-Present)

Bromocriptine, an ergot-derived dopamine agonist, was introduced in the 1970s and transformed the management of prolactinomas from a surgical problem to a medical one. It worked, but side effects (nausea, orthostatic hypotension, nasal congestion) limited tolerability. Cabergoline, introduced in the 1990s, offered longer duration of action (twice weekly dosing versus daily), superior efficacy, and better tolerability. By the 2000s, cabergoline had become first-line treatment for hyperprolactinemia worldwide.

The Expanding Role (1990s-2026)

Research since the 1990s has progressively expanded understanding of prolactin's functions far beyond lactation. Its roles in immune modulation, metabolic regulation, reproductive behavior, stress response, and brain development have been documented across hundreds of studies. The discovery that prolactin acts as a cytokine-like molecule -- signaling through the JAK-STAT pathway rather than classical hormone pathways -- reframed it as an immune mediator as much as an endocrine hormone.

In the bodybuilding and PED communities, awareness of prolactin's role in steroid side effects grew substantially through the 2000s and 2010s, making prolactin management a standard component of anabolic steroid cycle planning. The r/Prolactinoma subreddit and r/steroids community have become significant repositories of lived experience with both prolactin-related pathology and its pharmacological management.